Fierce Healthcare December 7, 2022
By Alison Lum, Edward Fotsch

This is the third in a series of articles that looks at the current state of drug cost transparency for prescribers, pharmacists, and patients. The first two articles can be found here and here.

The first and second articles in this series focused on the promise and challenges with real-time prescription benefit (RTPB), including the need to move beyond transparency solely when ordering new prescriptions through the electronic health record.

This third article expands the focus of drug cost transparency to include all of a patient’s current medications and all relevant points of patient care and communications.  While cost transparency to prescribers in EHRs is essential, there are many other relevant and important stakeholders in the care and communication processes,...

Today's Sponsors

Transcarent
SalesSparx

Today's Sponsor

Health Edge

 
Topics: Pharma, Pharma / Biotech
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
Amazon’s RxPass Doesn’t Yet Really Compete With Mark Cuban’s Cost Plus Drug Company
2023’s Biggest Pharma Cybersecurity Threats to Watch
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act

Share This Article